• Journal of Radiation Protection and Research
• /
• 제46권4호
• /
• pp.170-177
• /
• 2021

Background: The International Commission on Radiological Protection is preparing to provide reference dose coefficients for environmental radioiodine intake based on newly developed age-specific biokinetic models. However, the biokinetics of iodine has been reported to be strongly dependent on the dietary intake of stable iodine; for example, the thyroidal uptake of iodine may be substantially lower in iodine-rich regions than in iodine-deficient regions. Therefore, this study attempted to establish a system of age-specific thyroid dose estimation for South Koreans, whose daily iodine intakes are significantly higher than that of the world population. Materials and Methods: Korean age-specific biokinetic parameters and thyroid masses were derived based on the previously developed Korean adult model and the Korean anatomical reference data for adults, respectively. This study complied with the principles used in the development of age-specific biokinetic models for world population and used the ratios of baseline values for each age group relative to the value for adults to derive age-specific values. Results and Discussion: Biokinetic model predictions based on the Korean age-specific parameters showed significant differences in iodine behaviors in the body compared to those predicted using the model for the world population. In particular, the Korean age-specific thyroid dose coefficients for ¹²⁹I and ¹³¹I were considerably lower than those calculated for the world population (25%-76% of the values for the world population). Conclusion: These differences stress the need for Korean-specific internal dose assessments for infants and children, which can be achieved by using the data calculated in this study.

• 대한방사선기술학회지:방사선기술과학
• /
• 제31권1호
• /
• pp.11-16
• /
• 2008

목적: 갑상선 암 환자에서 방사성옥소($^{131}I$) 치료 시 체질량지수와 초기 유효선량 값의 상관관계를 알아보고, 또한 갑상선치료 환자로부터 1 m 떨어진 옆 사람에게 전달되는 유효선량 값을 측정하여 환자의 격리가 언제까지 필요한지 알아보고자 한다. 재료 및 방법: 치료당일 오전에 금식을 하게 하여 입원실에서 신장과 체중을 측정하였다. 방사성옥소($^{131}I$) 150 mCi를 환자에게 투여하기 전에 핵의학과에서 병에 들어있는 I-131 capsule을 방사선량 측정기[ATOMLAB DOSE CALIBRATORS(Biodex Medical Systems)]로 측정하여 기록 하여둔다. 치료적 용량 150 mCi(${\pm}6\;mCi$)를 투여받은 환자는 격리된 입원실에서 투여 후 바로 1 m 거리에서 초기 유효선량을 G-M survey meter로 측정하고 다음날 아침에도 같은 방법으로 선량을 측정하여 법정인 허용선량이 되면 퇴원 처방을 내고 $4{\sim}5$시간 후에 퇴원을 한다. 자료 분석은 Med calc Version 9,2,1,0통계 프로그램 이용하여 분석하였다. 결과: 초기 유효선량 값과 체질량지수 상관관계를 분석한 결과 Correlation coefficient 값이 음의 값으로 체질량지수가 증가할수록 초기 유효선량 값은 감소함을 알 수 있었다. 또한 P=0.0004로 유의한 결과임을 알 수 있었다. 체질량지수에 따른 group간의 비교를 하기위해 One-way ANOVA분석한 결과 체지방지수가 증가할수록 초기 유효선량 값이 감소하는 것을 알 수 있었다. 또한 P=0.007로 유의한 결과임을 알 수 있었다. 결론: 체질량지수와 초기선량과의 관계는 밀접한 상관관계가 있었고, 53%의 환자가 NRC규정에서 권고하는 선량을 만족시켜 1박2일 동안 입원을 하였다. 따라서 체질량지수와 초기 유효선량과의 관계를 잘 이용하게 되면 병실 회전율에 도움이 되리라 사료된다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권4호
• /
• pp.1859-1862
• /
• 2014

Recently, the main therapy of medullary thyroid cancer (MTC) is surgical, but by which way there is a poor prognosis with a mean survival of only 5 years. In some cases, some researchers found that it is the medullary thyroid cancer stem cells (MTCSCs) that cause metastasis and recurrence. This study aimed to eradicate MTCSCs through administration of all-trans-retinoic acid (ATRA). Here we demonstrate that MTCSCs possess stemlike properties in serum-free medium. The ABCG2, OCT4 and sodium iodide symporter (NIS) were changed by ATRA. Additionally, we found that ATRA can increase the expression of NIS in vivo. All the data suggested that ATRA could increase the iodine uptake of MTCSCs through NIS.

• 대한방사선기술학회지:방사선기술과학
• /
• 제39권3호
• /
• pp.385-390
• /
• 2016

방사성옥소를 이용한 2인 치료격리병실은 환자간의 불필요한 피폭선량을 유발하게 된다. 이에 본 연구에서는 방사성 옥소를 섭취 후 배설 없이 모두 인체에 분포하였다는 가정 하에 방사성 옥소의 물리적 특성 및 생물역동학적 정보를 제외한 보수적인 관점으로 몬테카를로 모의 모사를 이용한 2인 치료격리병실의 안전성을 평가하고자 한다. 실험 결과 방사성옥소에서 방출되는 364 keV의 감마선은 공기층 약 30 cm 또는 납 차폐체 3 mm가 반가층으로 작용됨을 파악할 수 있었으며, 환자간 거리 및 납 차폐체의 두께를 이용하였을 때, 입원기간(48시간)동안 상대방 환자로부터 받게 되는 외부 피폭선량은 5 mSv 이하로 법적 격리 기준선량 보다 낮게 나타남으로써 2인 치료격리병실의 효율적인 관리가 가능한 것으로 분석되었다.

• 대한핵의학회지
• /
• 제21권2호
• /
• pp.151-154
• /
• 1987

Total 114 patients were studied prospectively with radioiodine uptake (RAIU) and $^{99m}TcO_4^-$ thyroid scan to design a very simple, rapid and inexpensive method measuring the thyroid uptake on thyroid scan. After the RAIU was obtained at 24 hours after P.O. of $^{131}I$, Thyroid scan was performed at 20 minutes after LV. of $^{99m}TcO_4^-$ and the bilateral salivary glands were included in the scan field. Pinhole collimated and computer assisted gamma camera was used. Three regions of interest were set on each salivary gland and on the thyroid by automatic edge detection method. Mean counts per pixel were calculated for each ROI and the salivary-thyroid ratio (STR) was defined as; $$STR(%)=\frac{Mean\;counts\;per\;pixel\;of\;salivary\;glands\;(KC)}{Mean\;counts\;per\;pixel\;of\;thyroid\;gland\;(KC)}\times100$$ 114 cases consisted of 41 normal, 55 hyperthyroid and 18 hypothyroid patients and correlation between the STR and the RAID were evaluated in total and each group. The STR and the RAID showed reverse linear regression in 114 cases (r= -0.8, P=0) and closer correlation was shown in hyperthyroid group (r= -0_9, p=0). Mean STR in normal group was 47.6%. In predicting the RAID by STR, sensitivity and specificity were 88.3% and 64.9% in 114 cases and 95.3% and 83.3% in hyperthyroid group. It is recommended that the STR be used in place of the RAID giving same information at saving time, money and radiation exposure.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권6호
• /
• pp.2805-2810
• /
• 2016

Background: Differentiated thyroid cancer is the most common endocrine malignancy with a generally good prognosis. Knowing long-term outcomes of each patient helps management planning. The study was conducted to develop and validate a clinical prognostic score for predicting disease remission in patients with differentiated thyroid cancer based on patient, tumor and treatment factors. Materials and Methods: A retrospective cohort study of 1,217 differentiated thyroid cancer patients from two tertiary-care hospitals in the Northeast of Thailand was performed. Associations between potential clinical prognostic factors and remission were tested by Cox proportional-hazards analysis in 852 patients (development cohort). The prediction score was created by summation of score points weighted from regression coefficients of independent prognostic factors. Risks of disease remission were estimated and the derived score was then validated in the remaining 365 patients (validation cohort). Results: During the median follow-up time of 58 months, 648 (76.1%) patients in the development cohort had disease remission. Five independent prognostic factors were identified with corresponding score points: duration from thyroid surgery to $^{131}I$ treatment (0.721), distant metastasis at initial diagnosis (0.801), postoperative serum thyroglobulin level (0.535), anti-thyroglobulin antibodies positivity (0.546), and adequacy of serum TSH suppression (0.293). The total risk score for each patient was calculated and three categories of remission probability were proposed: ${\leq}1.628$ points (low risk, 83% remission), 1.629-1.816 points (intermediate risk, 87% remission), and ${\geq}1.817$ points (high risk, 93% remission). The concordance (C-index) was 0.761 (95% CI 0.754-0.767). Conclusions: The clinical prognostic scoring model developed to quantify the probability of disease remission can serve as a useful tool in personalized decision making regarding treatment in differentiated thyroid cancer patients.